osteoclast


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to osteoclast: calcitonin, osteoclast activating factor

os·te·o·clast

 (ŏs′tē-ə-klăst′)
n.
1. A large multinucleate cell found in growing bone that resorbs bony tissue, as in the formation of canals and cavities.
2. An instrument used in surgical osteoclasis.

[osteo- + Medieval Latin -clastēs, breaker (from Late Greek -klastēs, from Greek klastos, broken, from klān, to break).]

os′te·o·clas′tic adj.

osteoclast

(ˈɒstɪəʊˌklæst)
n
1. (Surgery) a surgical instrument for fracturing bone
2. (Physiology) a large multinuclear cell formed in bone marrow that is associated with the normal absorption of bone
ˌosteoˈclastic adj

os•te•o•clast

(ˈɒs ti əˌklæst)

n.
1. a skeletal cell that functions in bone formation.
2. a surgical instrument for effecting osteoclasis.
[1870–75; osteo- + -clast < Greek klastós broken]
os`te•o•clas′tic, adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.osteoclast - cell that functions in the breakdown and resorption of bone tissue
bone cell - a cell that is part of a bone
Translations
Osteoklast
luunsyöjäsolu

os·te·o·clast

n. osteoclasto, célula gigante multinucleada que participa en la formación de tejido óseo y reemplaza al cartílago durante la osificación.
References in periodicals archive ?
In contrast, LPNS decreased the numbers of osteoclast precursor cells ([CD117.
The key signalling protein for osteoclast differentiation is RANKL, which attaches to a receptor that is widely expressed on osteoclasts--RANK.
Validation of the osteoclast phenotype will be confirmed through staining for multiple nuclei using hematoxylin and eosin (H&E) staining and the activity of tartrate-resistant acid phosphatase (TRAP).
The study on mice found that it later powerfully promotes the activities of osteoclast, a cell that destroys bones.
MicroRNAs can reduce that forced labor by inhibiting osteoclast proteins and thus limiting the number of osteoclasts present.
Osteoblasts not only play a central role in bone formation by synthesizing several bone matrix proteins, but regulate osteoclast maturation through expression of soluble factors RANKL and M-CSF, resulting in bone resorption.
It was shown that isoflavonoid glabridin could inhibit osteoclast maturation.
Unlike traditional antiresorptive drugs like bisphosphonates, however, odanacatib does not interfere with the function of the entire osteoclast or reduce the number of osteoclasts.
Thus there has already been a study proposing an imaging agent for the detection of the osteoclast number in bone metastases in a small animal model by applying radiolabeled RGD peptides to detect osteoclasts in lytic bone lesions [1].
The resorption process starts with the stimulation of osteoclast development when bone tissue presents microcracks and deformation.
RANKL promotes osteoclast differentiation and activation, and denosumab prevents RANKL from engaging the RANK receptor on osteoclasts and osteoclast precursors thereby reducing osteoclast mediated bone resorption and increasing bone density.
The bisphosphonates, which are non-metabolized synthetic analogs of pyrophosphate synthetase, function through their inhibition of osseous resorption via suppression of osteoclast activity.